Gilead Sciences Target Price

Analysts' average 12-month price target for Gilead Sciences is $150.

Get informed when a big investor buys or sells

+ Follow

Share Price

$147.5

Average Target Price

$147.33

0.1% downside

9 analysts in the last 4 months

High: $175 | Low: $120

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

Date	Analyst	Price Target	Current Upside/Downside
2026-09-10	HSBCMorten Herholdt	$175	18.6% upside
2026-08-05	Truist Financial	$150	1.7% upside
2026-08-05	RBC Capital	$123	16.6% downside
2026-07-29	Barclays	$145	1.7% downside
2026-07-27	Morgan Stanley	$165	11.9% upside
2026-07-20	Leerink PartnersDaina Graybosch	$127	13.9% downside
2026-07-08	Morgan Stanley	$166	12.5% upside
2026-07-07	RBC CapitalBrian Abrahams	$120	18.6% downside
2026-07-06	HSBCRajesh Kumar	$155	5.1% upside
2026-06-01	RBC CapitalBrian Abrahams	$122	17.3% downside
2026-05-20	Maxim GroupMichael Okunewitch	$165	11.9% upside
2026-05-10	Morgan Stanley	$168	13.9% upside
2026-05-08	Truist Financial	$157	6.4% upside
2026-04-10	Morgan Stanley	$175	18.6% upside
2026-04-08	Truist FinancialGregory Renza	$155	5.1% upside
2026-03-10	JefferiesAkash Tewari	$180	22% upside
2026-02-19	Barclays	$155	5.1% upside
2026-02-19	Mizuho Securities	$170	15.3% upside
2026-02-18	UBS	$175	18.6% upside
2026-02-11	Robert W. Baird	$145	1.7% downside
2026-02-11	BMO CapitalEvan Seigerman	$160	8.5% upside
2026-02-11	Truist Financial	$152	3.1% upside
2026-02-11	Cantor Fitzgerald	$155	5.1% upside
2026-02-11	ScotiabankLouise Chen	$177	20% upside
2026-02-11	Oppenheimer	$165	11.9% upside
2026-02-11	NeedhamJoseph Stringer	$170	15.3% upside
2026-02-11	Truist Financial	$162	9.8% upside
2026-02-11	Morgan Stanley	$171	15.9% upside
2026-02-11	BernsteinCourtney Breen	$160	8.5% upside
2026-02-11	Wells FargoMohit Bansal	$165	11.9% upside
2026-01-27	Truist Financial	$145	1.7% downside
2026-01-26	BMO CapitalEvan David Seigerman	$150	1.7% upside
2026-01-26	UBS	$155	5.1% upside
2026-01-13	Morgan Stanley	$150	1.7% upside
2026-01-07	UBSMichael Yee	$145	1.7% downside
2025-12-29	BernsteinCourtney Breen	$135	8.5% downside
2025-12-15	Wolfe ResearchAlexandria Hammond	$150	1.7% upside
2025-12-12	Morgan Stanley	$151	2.4% upside
2025-12-10	HSBC	$133	9.8% downside
2025-11-25	BMO CapitalEvan David Seigerman	$135	8.5% downside
2025-11-24	Truist FinancialGregory Renza	$140	5.1% downside
2025-11-20	Mizuho Securities	$140	5.1% downside
2025-10-31	Wells Fargo	$145	1.7% downside
2025-10-31	RBC Capital	$105	28.8% downside
2025-10-31	Morgan StanleyTerence Flynn	$147	0.3% downside
2025-10-09	Cantor FitzgeraldCarter Gould	$135	8.5% downside
2025-10-06	Wells Fargo	$140	5.1% downside
2025-08-11	Deutsche BankJames Shin	$135	8.5% downside
2025-08-08	Morgan StanleyTerence Flynn	$143	3.1% downside
2025-08-08	Robert W. BairdBrian Skorney	$108	26.8% downside

Gilead Sciences (GILD) FAQ

Gilead Sciences (GILD) currently reports a target price of $150. Use the charts on this page to explore Gilead Sciences's target price history and peer comparisons.

Analysts' average 12-month price target for Gilead Sciences is $150, about 0.1% downside from the current share price of $147.5. That spread summarizes where covering analysts expect the stock could trade over the next year, not a guarantee. Review the individual firm targets on this page — a wide high-to-low range often means opinion is split.

Start with the current target price of $150, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Gilead Sciences, and consider following GILD for alerts when major investors trade the stock.

Gilead Sciences is classified in the Healthcare sector. On target price, it currently shows $150. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing GILD with unrelated industries.